Monovalent XBB.1.5 COVID-19 vaccine effectiveness against hospitalisations and deaths during the Omicron BA.2.86/JN.1 period among older adults in seven European countries: A VEBIS-EHR network study

Monovalent XBB.1.5 vaccine had a moderate protective effect against severe and fatal COVID-19 likely caused by BA.2.86/JN.1 during the 2023/2024 winter, among persons aged ≥65.

Authors

Institutions

Publication Details

Journal
Expert Review of Vaccines
Published
2024-11-13
DOI
https://doi.org/10.1080/14760584.2024.2428800
Citations
21
Primary Topic
Heparin-Induced Thrombocytopenia and Thrombosis
Type
article
Field-Weighted Citation Impact
12.03
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Monovalent XBB.1.5 COVID-19 vaccine effectiveness against hospitalisations and deaths during the Omicron BA.2.86/JN.1 period among older adults in seven European countries: A VEBIS-EHR network study

James Humphreys, Toon Braeye, Jesús Castilla, Ida Rask Moustsen‐Helms et al.
21 citations
Expert Review of Vaccines
Heparin-Induced Thrombocytopenia and Thrombosis
12.03
article

Monovalent XBB.1.5 COVID-19 vaccine effectiveness against hospitalisations and deaths during the Omicron BA.2.86/JN.1 period among older adults in seven European countries: A VEBIS-EHR network study

James Humphreys, Toon Braeye, Jesús Castilla, Ida Rask Moustsen‐Helms, Susana Monge, Hinta Meijerink, Nicklas Pihlström, Carla Nunes, Izaak Van Evercooren, Massimo Fabiani, Sabrina Bacci, Ausenda Machado, Nathalie Nicolay, Chiara Sacco, Christian Holm Hansen, Anthony Nardone, Patrícia Soares, Rickard Ljung, Iván Martínez‐Baz
article en
21 citations

Abstract

Monovalent XBB.1.5 vaccine had a moderate protective effect against severe and fatal COVID-19 likely caused by BA.2.86/JN.1 during the 2023/2024 winter, among persons aged ≥65.

Expert Review of VaccinesVol. 23(1)
Statens Serum Institut (DK), Medical Products Agency (SE), Norwegian Institute of Public Health (NO), Istituto Superiore di Sanità (IT), Instituto de Salud Carlos III (ES), Ricardo (United Kingdom) (GB), Instituto de Salud Pública de Navarra (ES), Centre for Biomedical Network Research on Rare Diseases (ES), Instituto Nacional de Saúde (MZ), National Institute of Health Dr. Ricardo Jorge (PT), Sciensano (Belgium) (BE), Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (ES), European Centre for Disease Prevention and Control (SE)
Good health and well-being
Openalex Percentile: Top 1%
Heparin-Induced Thrombocytopenia and Thrombosis
12.03
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.